Tunisia's Heartbeat : Pioneering Isotopic Techniques in Cardiac Viability Among Resource Challenges

##plugins.themes.academic_pro.article.sidebar##

Published Dec 27, 2025
https://doi.org/10.62438/tunismed.v103i10.5956
Download
pdf
Vol. 103 No. 10 (2025): Tunis Med Oct 2025

##plugins.themes.academic_pro.article.main##

Raja Sfar
Department of Nuclear medicine, Sahloul Hospital, Faculty of Medicine of Monastir, Tunisia
Meriem Ouachem
Department of Nuclear medicine, Sahloul Hospital, Faculty of Medicine of Monastir, Tunisia
Sameh Ben Farhat
Department of cardiology, Sahloul Hospital, Faculty of medicine of Sousse, Tunisia
Elyes Neffati
Department of cardiology, Sahloul Hospital, Faculty of medicine of Sousse, Tunisia
Chayma Landolsi
Department of Nuclear medicine, Sahloul Hospital, Faculty of Medicine of Monastir, Tunisia
Kaouther Chatti
Department of Nuclear medicine, Sahloul Hospital, Faculty of Medicine of Monastir, Tunisia

Abstract

Introduction: In Tunisia, where healthcare resources are often limited, nuclear imaging techniques are revolutionizing cardiac care. They provide critical information on myocardial perfusion, contractile function, and metabolic processes, transforming the ischemic heart disease management.


Aim: This study explores the essential role of isotopic examinations in assessing myocardial viability and evaluates their impact on therapeutic decision-making.


 Methods: A prospective descriptive and analytical study was conducted on 40 patients for whom myocardial viability studies were indicated. All patients underwent isotopic examinations and coronary angiographies performed between January 2022 and June 2023. Results: Myocardial viability scintigraphy (MVS) showed that 62.5% of myocardial territories were non-viable, while 37.5% were hibernating. These results perfectly matched those obtained by 18FDG PET-CT. MVS proved to be a highly reliable tool that significantly influenced therapeutic decisions. Revascularization was indicated in 40% of patients with viable myocardium, while medical treatment was prescribed for all patients with non-viable myocardium. During a follow-up period, a significant improvement in left ventricular ejection fraction (LVEF) was observed in the group of patients with hibernating myocardium treated with revascularization compared to those treated medically (p=0.02). Additionally, non-viable group had a higher mortality rate (12%) compared to viable group (6.7%). Survival rates were better in the group with viable lesions (93% vs 85%).


Conclusions: This is the first prospective study conducted in Tunisia assessing the contribution of isotopic examinations in evaluating myocardial viability. The diagnostic value of MVS is comparable to metabolic imaging. Furthermore, nuclear imaging techniques can influence therapeutic ....(abstract truncated at 250 words).


 

Keywords:

Myocardial scintigraphy, PET-CT, 18FDG, viability, ischemic heart disease, revascularization

##plugins.themes.academic_pro.article.details##

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

References

  1. Milouchi S, Fekih R, Lassoued T, Salah M, Ellini H. Facteurs de risque cardiovasculaire : nouveautés 2020 Cardiovascular risk factors: what’s new in 2020. 2019;15.
  2. N’Guetta R, Yao H, Ekou A, N’Cho-Mottoh MP, Angoran I, Tano M, et al. Prévalence et caractéristiques des syndromes coronariens aigus dans une population d’Afrique subsaharienne. Ann Cardiol Angéiologie. 2016 Apr 1;65(2):59–63.
  3. Pasquet A, Robert A, D’Hondt AM, Dion R, Melin JA, Vanoverschelde JLJ. Prognostic Value of Myocardial Ischemia and Viability in Patients With Chronic Left Ventricular Ischemic Dysfunction. Circulation. 1999 Jul 13;100(2):141–8.
  4. Underwood S. Imaging techniques for the assessment of myocardial hibernation Report of a Study Group of the European Society of Cardiology. Eur Heart J. 2004 May;25(10):815–36.
  5. Zouaoui W, Ouldzein H, Carrié D. Étude de la viabilité myocardique dans le post-infarctus et indications de la revascularisation. Ann Cardiol Angéiologie. 2010 Apr;59(2):79–85.
  6. Garcia MJ, Kwong RY, Scherrer-Crosbie M, Taub CC, Blankstein R, Lima J, et al. State of the Art: Imaging for Myocardial Viability: A Scientific Statement From the American Heart Association. Circ Cardiovasc Imaging. 2020 Jan;13(7):e000053.
  7. Khalaf S, Al-Mallah MH. Fluorodeoxyglucose Applications in Cardiac PET: Viability, Inflammation, Infection, and Beyond. Methodist DeBakey Cardiovasc J. 2020;16(2):122–9.
  8. Cerqueira MD, Weissman NJ, Dilsizian V, Jacobs AK, Kaul S, Laskey WK, et al. Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart. A statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. Circulation. 2002 Jan 29;105(4):539–42.
  9. Letter: Grading of angina pectoris. [Internet]. [cited 2024 Mar 13]. Available from: https://www.ahajournals.org/doi/epdf/10.1161/circ.54.3.947585
  10. 1. Dolgin M New York Heart Association Criteria Committee. Nomenclature and Criteria for Diagnosis of Diseases of the Heart and Great Vessels. 9th ed. Little Brown; 1994.
  11. Allman KC, Shaw LJ, Hachamovitch R, Udelson JE. Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction: a meta-analysis. J Am Coll Cardiol. 2002 Apr;39(7):1151–8.
  12. Velazquez EJ, Lee KL, Deja MA, Jain A, Sopko G, Marchenko A, et al. Coronary-Artery Bypass Surgery in Patients with Left Ventricular Dysfunction. N Engl J Med. 2011 Apr 28;364(17):1607–16.
  13. Bonow RO, Maurer G, Lee KL, Holly TA, Binkley PF, Desvigne-Nickens P, et al. Myocardial Viability and Survival in Ischemic Left Ventricular Dysfunction. N Engl J Med. 2011 Apr 28;364(17):1617–25.
  14. Ghosh N, Rimoldi OE, Beanlands RSB, Camici PG. Assessment of myocardial ischaemia and viability: role of positron emission tomography. Eur Heart J. 2010 Dec;31(24):2984–95.
  15. Kandolin RM, Wiefels CC, Mesquita CT, Chong AY, Boland P, Glineur D, et al. The Current Role of Viability Imaging to Guide Revascularization and Therapy Decisions in Patients With Heart Failure and Reduced Left Ventricular Function. Can J Cardiol. 2019 Aug;35(8):1015–29.
  16. Kaltoft, Morten Bøttcher, Niels Pet A. 99m Tc-Sestamibi SPECT is a Useful Technique for Viability Detection. Results of a Comparison with NH 3 /FDG PET. Scand Cardiovasc J. 2001 Jan;35(4):245–51.
  17. Sorrentino AR, Acampa W, Petretta M, Mainolfi C, Salvatore M, Cuocolo A. Comparison of the prognostic value of SPECT after nitrate administration and metabolic imaging by PET in patients with ischaemic left ventricular dysfunction. Eur J Nucl Med Mol Imaging. 2007 Apr;34(4):558–62.
  18. Sinusas AJ, Watson DD, Cannon JM, Beller GA. Effect of ischemia and postischemic dysfunction on myocardial uptake of technetium-99m-labeled methoxyisobutyl isonitrile and thallium-201. J Am Coll Cardiol. 1989 Dec;14(7):1785–93.
  19. Okada RD, Glover D, Gaffney T, Williams S. Myocardial kinetics of technetium-99m-hexakis-2-methoxy-2-methylpropyl-isonitrile. Circulation. 1988 Feb;77(2):491–8.
  20. Medrano R, Lowry RW, Young JB, Weilbaecher DG, Michael LH, Afridi I, et al. Assessment of myocardial viability with 99mTc sestamibi in patients undergoing cardiac transplantation. A scintigraphic/pathological study. Circulation. 1996 Sep 1;94(5):1010–7.
  21. Maes AF, Borgers M, Flameng W, Nuyts JL, van de Werf F, Ausma JJ, et al. Assessment of myocardial viability in chronic coronary artery disease using technetium-99m sestamibi SPECT. Correlation with histologic and positron emission tomographic studies and functional follow-up. J Am Coll Cardiol. 1997 Jan;29(1):62–8.
  22. Dakik HA, Howell JF, Lawrie GM, Espada R, Weilbaecher DG, He ZX, et al. Assessment of myocardial viability with 99mTc-sestamibi tomography before coronary bypass graft surgery: correlation with histopathology and postoperative improvement in cardiac function. Circulation. 1997 Nov 4;96(9):2892–8.
  23. Bisi G, Sciagrà R, Santoro GM, Fazzini PF. Rest technetium-99m sestamibi tomography in combination with short-term administration of nitrates: feasibility and reliability for prediction of postrevascularization outcome of asynergic territories. J Am Coll Cardiol. 1994 Nov 1;24(5):1282–9.
  24. Tillisch J, Brunken R, Marshall R, Schwaiger M, Mandelkern M, Phelps M, et al. Reversibility of Cardiac Wall-Motion Abnormalities Predicted by Positron Tomography. N Engl J Med. 1986 Apr 3;314(14):884–8.
  25. Sciagrà R, Leoncini M, Marcucci G, Dabizzi RP, Pupi A. Technetium-99m sestamibi imaging to predict left ventricular ejection fraction outcome after revascularisation in patients with chronic coronary artery disease and left ventricular dysfunction: comparison between baseline and nitrate-enhanced imaging. Eur J Nucl Med. 2001 Jun;28(6):680–7.